Magnetic Resonance Imaging-Guided Brachytherapy in Treating Patients with Gynecologic Cancers

Inclusion Criteria

• Participants must have histologically or cytologically confirmed carcinoma; central pathology review is not required; however, pathology will be reviewed at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins
• Any patient eligible for internal implantation without MR guidance will be considered eligible for this protocol; standard criteria for internal implantation include: * Carcinoma of the cervix: stage I-IVA or vaginal recurrence * Carcinoma of the uterus: stage IIIB (vaginal involvement), inoperable, or vaginal recurrence * Carcinoma of the vagina: stage I-IVA or vaginal recurrence * Carcinoma of the vulva: stage I-IVA or recurrence * Carcinoma of the urethra based on treating physician’s discretion
• Patients who have received prior radiation or chemotherapy may be enrolled on this study
• Life expectancy of greater than 6 months
• Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 or greater, based on treating physician’s discretion
• MRI of the pelvis or positron emission tomography (PET)-CT within 4 months before registration
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Absolute neutrophil count < 500 at the time of enrollment
• A history of metal in the head or eyes